Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The efficacy of a third dose of the COVID-19 vaccine in HCT, CAR-T and BiTE recipients

In this video, Muhammad Bilal Abid, MD, MRCP, Medical College of Wisconsin, Milwaukee, WI, discusses the results from a study which investigated the efficacy of administering a third dose of the COVID-19 mRNA vaccine to recipients of hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell (CAR-T), and bispecific T-cell engager therapies (BiTEs). Although these patients had not seroconverted after the first two doses of the vaccine, 59% of patients in this study developed protective antibodies following the third dose. Dr Abid further discusses the results of this study, including the antibody titers in myeloma patients versus lymphoma patients, and the seroconversion rates in myeloma BiTE recipients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).